Finite therapy of chronic hepatitis B infection: Cons-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Finite therapy of chronic hepatitis B infection: Cons

Published:2024-01 Issue:1 Volume:23 Page:
ISSN:2046-2484
Container-title:Clinical Liver Disease
language:en
Short-container-title:

Author:

Hsu Yao-Chun¹²³⁴^ORCID

Affiliation:

1. Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan

2. Graduate Institute of Medicine and School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan

3. Department of Internal Medicine, Fu-Jen Catholic University Hospital, New Taipei, Taiwan

4. Institute of Biomedical Informatics, College of Medicine, National Yang-Ming University, Taipei, Taiwan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference11 articles.

1. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients;Kao;Hepatol Int,2021

2. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study);Hirode;Gastroenterology,2022

3. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: A meta-analysis;Hall;Gut,2022

4. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies;Liu;Liver Int,2022

5. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm;Hsu;Clin Mol Hepatol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP